BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Antibody-drug conjugates are coming of age with a remarkable s
 urge in recent times\, which has marked a turning point in their developm
 ent. Notable achievements include the ground-shaking triumph of ENHERTU\,
  eye-popping investments like Pfizer's monumental $43 billion acquisition
  of Seagen\, and the FDA's greenlight for ELAHERE. These milestones have 
 transformed the ADC landscape\, driving increased interest and investment
  in the field\, which now has a preclinical and clinical arena dynamicall
 y evolving.\n\nAs such\, the 14th World ADC London returns next March. Th
 is will be the first opportunity in the new year to explore these monumen
 tal wins\, reflect on ongoing challenges\, and collaborate on innovative 
 strategies to supercharge all stages of ADC development.\n\nSecure regula
 tory approvals and position ADCs at the forefront of revolutionary therap
 ies with exclusive insights into linker-payload optimization\, pioneering
  target discovery\, strategic toxicity management\, precise combination p
 artner selection\, and rapid manufacturing advancements.\n\nNo ADC stone 
 was left unturned as we united 600+ leading players in the field under on
 e roof including AbbVie\, AstraZeneca\, Daiichi Sankyo\, GlaxoSmithKline\
 , Immunogen\, Regeneron\, Seagen\, and many more.\n\nDate and Time: On Tu
 e\, 12 Mar 2024 08:00 - Fri\, 15 Mar 2024 17:00\n
DTEND:20240315T170000
DTSTAMP:20260416T141201Z
DTSTART:20240312T080000
LOCATION:ExCeL London\, 1 Western Gateway\, London\, England\, E16 1XL\,
SEQUENCE:0
SUMMARY:Antibody-drug conjugates are coming of age with a remarkable surge
  in recent times\, which has marked a turning point in their development.
  Notable...
UID:ceafd3a5-145f-4310-8d80-6fec80aea4c0
END:VEVENT
END:VCALENDAR